Precision BioSciences, Inc. (DTIL): Price and Financial Metrics
GET POWR RATINGS... FREE!
DTIL POWR Grades
- Value is the dimension where DTIL ranks best; there it ranks ahead of 89.98% of US stocks.
- DTIL's strongest trending metric is Value; it's been moving up over the last 179 days.
- DTIL ranks lowest in Momentum; there it ranks in the 4th percentile.
DTIL Stock Summary
- Precision Biosciences Inc's stock had its IPO on March 28, 2019, making it an older stock than merely 9.5% of US equities in our set.
- Revenue growth over the past 12 months for Precision Biosciences Inc comes in at 375.72%, a number that bests 97.8% of the US stocks we're tracking.
- The volatility of Precision Biosciences Inc's share price is greater than that of 90.9% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to Precision Biosciences Inc, a group of peers worth examining would be IDYA, PLRX, WVE, SRPT, and JNCE.
- DTIL's SEC filings can be seen here. And to visit Precision Biosciences Inc's official web site, go to www.precisionbiosciences.com.
DTIL Valuation Summary
- In comparison to the median Healthcare stock, DTIL's price/sales ratio is 34.8% lower, now standing at 7.4.
- Over the past 30 months, DTIL's EV/EBIT ratio has gone up 3.7.
- Over the past 30 months, DTIL's price/sales ratio has gone down 71.2.
Below are key valuation metrics over time for DTIL.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DTIL | 2021-08-31 | 7.4 | 7.4 | -16.1 | -12.6 |
| DTIL | 2021-08-30 | 6.9 | 7.0 | -15.1 | -11.5 |
| DTIL | 2021-08-27 | 6.8 | 6.9 | -14.8 | -11.3 |
| DTIL | 2021-08-26 | 6.4 | 6.4 | -13.9 | -10.4 |
| DTIL | 2021-08-25 | 6.2 | 6.2 | -13.5 | -10.0 |
| DTIL | 2021-08-24 | 6.0 | 6.0 | -13.0 | -9.5 |
DTIL's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DTIL has a Quality Grade of C, ranking ahead of 57.32% of graded US stocks.
- DTIL's asset turnover comes in at 0.5 -- ranking 82nd of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows DTIL's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.500 | 1 | -1.846 |
| 2021-03-31 | 0.176 | 1 | -3.839 |
| 2020-12-31 | 0.135 | 1 | -3.174 |
| 2020-09-30 | 0.109 | 1 | -3.116 |
| 2020-06-30 | 0.087 | 1 | -3.034 |
| 2020-03-31 | 0.097 | 1 | -2.717 |
DTIL Price Target
For more insight on analysts targets of DTIL, see our DTIL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $19.13 | Average Broker Recommendation | 1.45 (Moderate Buy) |
DTIL Stock Price Chart Interactive Chart >
DTIL Price/Volume Stats
| Current price | $1.63 | 52-week high | $14.38 |
| Prev. close | $1.55 | 52-week low | $1.49 |
| Day low | $1.50 | Volume | 665,471 |
| Day high | $1.65 | Avg. volume | 660,128 |
| 50-day MA | $2.40 | Dividend yield | N/A |
| 200-day MA | $6.83 | Market Cap | 101.35M |
Precision BioSciences, Inc. (DTIL) Company Bio
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
Latest DTIL News From Around the Web
Below are the latest news stories about Precision Biosciences Inc that investors may wish to consider to help them evaluate DTIL as an investment opportunity.
Executive voice: New leader joins Durham biotech chasing permanent curesA personal experience at a young age inspired Michael Amoroso’s career in health care. Now, he's at the helm of a Durham company developing new treatments. |
Moderna (MRNA) Beats Q4 Earnings and Revenue EstimatesModerna (MRNA) delivered earnings and revenue surprises of 14.85% and 7.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock? |
What to Expect From Precision BioSciences (DTIL) Q4 EarningsOn Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline. |
Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should KnowPrecision BioSciences (DTIL) closed the most recent trading day at $4.82, moving -0.62% from the previous trading session. |
A Potential 10X Biotech PlayGene therapy saves a life … a small biotech that could be a 10X winner … keep your eyes on the entire biotech sector for great set-ups over the coming quarters Paddy Doherty’s father was in his 60s when he began getting breathless on walks. Doctors believed it was angina, but two years later when Doherty’s father died of a heart attack, the real culprit was identified – a rare disease called transthyretin (ATTR) amyloidosis. It’s a terrible, progressive health condition that’s ultimately fatal.I |
DTIL Price Returns
| 1-mo | -22.01% |
| 3-mo | -61.92% |
| 6-mo | -81.66% |
| 1-year | -85.28% |
| 3-year | -88.32% |
| 5-year | N/A |
| YTD | -77.97% |
| 2021 | -11.27% |
| 2020 | -39.96% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...